SE0301373D0 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
SE0301373D0
SE0301373D0 SE0301373A SE0301373A SE0301373D0 SE 0301373 D0 SE0301373 D0 SE 0301373D0 SE 0301373 A SE0301373 A SE 0301373A SE 0301373 A SE0301373 A SE 0301373A SE 0301373 D0 SE0301373 D0 SE 0301373D0
Authority
SE
Sweden
Prior art keywords
novel compounds
imidazo
formula
methods
pharmaceutical compositions
Prior art date
Application number
SE0301373A
Other languages
English (en)
Inventor
Martin Hemmerling
Thomas Klingstedt
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0301373A priority Critical patent/SE0301373D0/sv
Publication of SE0301373D0 publication Critical patent/SE0301373D0/sv
Priority to DE602004011330T priority patent/DE602004011330T2/de
Priority to AU2004236144A priority patent/AU2004236144B2/en
Priority to MXPA05012025A priority patent/MXPA05012025A/es
Priority to ES04731525T priority patent/ES2298754T3/es
Priority to PL04731525T priority patent/PL1625126T3/pl
Priority to PCT/SE2004/000694 priority patent/WO2004099204A1/en
Priority to EP07119970A priority patent/EP1887007A3/en
Priority to JP2006508045A priority patent/JP2006525997A/ja
Priority to DK04731525T priority patent/DK1625126T3/da
Priority to EP04731525A priority patent/EP1625126B1/en
Priority to CA002524624A priority patent/CA2524624A1/en
Priority to AT04731525T priority patent/ATE384061T1/de
Priority to US10/556,228 priority patent/US20060287355A1/en
Priority to CNA200480012617XA priority patent/CN1784402A/zh
Priority to PT04731525T priority patent/PT1625126E/pt
Priority to BRPI0410081-6A priority patent/BRPI0410081A/pt
Priority to SI200430618T priority patent/SI1625126T1/sl
Priority to CY20081100279T priority patent/CY1107301T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
SE0301373A 2003-05-09 2003-05-09 Novel compounds SE0301373D0 (sv)

Priority Applications (19)

Application Number Priority Date Filing Date Title
SE0301373A SE0301373D0 (sv) 2003-05-09 2003-05-09 Novel compounds
SI200430618T SI1625126T1 (sl) 2003-05-09 2004-05-06 Imidazo- in tiazolopiridini kot inhibitorji JAK3-kinaze
JP2006508045A JP2006525997A (ja) 2003-05-09 2004-05-06 Ｊａｋ３キナーゼ阻害剤としてのイミダゾ及びチアゾロピリジン
EP04731525A EP1625126B1 (en) 2003-05-09 2004-05-06 Imidazo and thiazolopyridines as jak3 kinase inhibitors
MXPA05012025A MXPA05012025A (es) 2003-05-09 2004-05-06 Imidazo y tiazolopiridinas como inhibidores de cinasa jak3.
ES04731525T ES2298754T3 (es) 2003-05-09 2004-05-06 Imidazo- y tiazolopiridinas como inhibidores de jak3 quinasa.
PL04731525T PL1625126T3 (pl) 2003-05-09 2004-05-06 Imidazo- i tiazolopirydyny jako inhibitory kinazy JAK3
PCT/SE2004/000694 WO2004099204A1 (en) 2003-05-09 2004-05-06 Imidazo and thiazolopyridines as jak3 kinase inhibitors
EP07119970A EP1887007A3 (en) 2003-05-09 2004-05-06 Imidazo- and Thiazolopyridine as JAK3 Kinase Inhibitors
DE602004011330T DE602004011330T2 (de) 2003-05-09 2004-05-06 Imidazo- und thiazolopyridine als jak3-kinase-inhibitoren
DK04731525T DK1625126T3 (da) 2003-05-09 2004-05-06 Imidazo- og thiazolopyridiner som JAK3-kinaseinhibitorer
AU2004236144A AU2004236144B2 (en) 2003-05-09 2004-05-06 Imidazo and thiazolopyridines as JAK3 kinase inhibitors
CA002524624A CA2524624A1 (en) 2003-05-09 2004-05-06 Imidazo and thiazolopyridines as jak3 kinase inhibitors
AT04731525T ATE384061T1 (de) 2003-05-09 2004-05-06 Imidazo- und thiazolopyridine als jak3-kinase- inhibitoren
US10/556,228 US20060287355A1 (en) 2003-05-09 2004-05-06 Imidazo and thiazolopyridines as jak3 kinase inhibitors
CNA200480012617XA CN1784402A (zh) 2003-05-09 2004-05-06 用作jak3激酶抑制剂的咪唑并和噻唑并吡啶化合物
PT04731525T PT1625126E (pt) 2003-05-09 2004-05-06 Imidazo- e tiazolopiridinas como inibidores de cinase jak3
BRPI0410081-6A BRPI0410081A (pt) 2003-05-09 2004-05-06 composto, composição farmacêutica, método de tratamento de uma doença ou condição mediada por jak3, e, processo para a preparação de um composto
CY20081100279T CY1107301T1 (el) 2003-05-09 2008-03-12 Ιμιδαζο και θειαζολοπυριδινες ως αναστολεις κινασης jak3

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0301373A SE0301373D0 (sv) 2003-05-09 2003-05-09 Novel compounds

Publications (1)

Publication Number Publication Date
SE0301373D0 true SE0301373D0 (sv) 2003-05-09

Family

ID=20291271

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0301373A SE0301373D0 (sv) 2003-05-09 2003-05-09 Novel compounds

Country Status (17)

Country Link
US (1) US20060287355A1 (sv)
EP (2) EP1887007A3 (sv)
JP (1) JP2006525997A (sv)
CN (1) CN1784402A (sv)
AT (1) ATE384061T1 (sv)
AU (1) AU2004236144B2 (sv)
BR (1) BRPI0410081A (sv)
CA (1) CA2524624A1 (sv)
CY (1) CY1107301T1 (sv)
DE (1) DE602004011330T2 (sv)
DK (1) DK1625126T3 (sv)
ES (1) ES2298754T3 (sv)
MX (1) MXPA05012025A (sv)
PL (1) PL1625126T3 (sv)
PT (1) PT1625126E (sv)
SE (1) SE0301373D0 (sv)
WO (1) WO2004099204A1 (sv)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0301372D0 (sv) * 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
US7884109B2 (en) 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
BRPI0610514A2 (pt) * 2005-04-05 2016-11-16 Pharmacopeia Inc composto, composição farmacêutica, e, método de tratamento de um distúrbio
EP2251341A1 (en) * 2005-07-14 2010-11-17 Astellas Pharma Inc. Heterocyclic Janus kinase 3 inhibitors
US8163767B2 (en) 2005-07-14 2012-04-24 Astellas Pharma Inc. Heterocyclic Janus Kinase 3 inhibitors
WO2007019191A2 (en) * 2005-08-08 2007-02-15 Janssen Pharmaceutica, N.V. Thiazolopyrimidine kinase inhibitors
CA2621261C (en) 2005-09-22 2014-05-20 Incyte Corporation Azepine inhibitors of janus kinases
DK2343299T3 (en) 2005-12-13 2016-01-18 Incyte Holdings Corp Heteroberl-substituted pyrrolo [2,3-b] pyridines and pyrrolo [2,3-b] pyrimidines as Janus kinase inhibitors
US7989459B2 (en) 2006-02-17 2011-08-02 Pharmacopeia, Llc Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
EP1900729A1 (en) * 2006-09-15 2008-03-19 Novartis AG Benzoxazoles and oxazolopyridines being useful as Janus kinases inhibitors
AR063141A1 (es) 2006-10-04 2008-12-30 Pharmacopeia Inc Derivados de 2- ( benzimidazolil ) purina 8- sustituida para inmunosupresion
TW200831104A (en) 2006-10-04 2008-08-01 Pharmacopeia Inc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
US7902187B2 (en) 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
ES2415863T3 (es) 2006-12-22 2013-07-29 Incyte Corporation Heterociclos sustituidos como inhibidores de Janus Quinasas
ES2627221T3 (es) 2006-12-28 2017-07-27 Rigel Pharmaceuticals, Inc. Compuestos de heterocicloalquiloxibenzamida N-sustituidos y métodos de uso
AR064879A1 (es) * 2007-01-12 2009-04-29 Astellas Pharma Inc Compuesto de piridina condensado
ES2575797T3 (es) 2007-06-13 2016-07-01 Incyte Holdings Corporation Sales del inhibidor de cinasas Janus (R)-3-(4-(7H-pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il)-3-ciclopentilpropanonitrilo
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
WO2009001021A1 (en) * 2007-06-26 2008-12-31 Chroma Therapeutics Ltd. Imidazopyridine derivatives useful as enzyme inhibitors for the treatment of cell proliferative and autoimmune diseases
EP2220068B1 (en) 2007-11-16 2016-01-27 Incyte Holdings Corporation 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
ATE513832T1 (de) * 2007-12-19 2011-07-15 Genentech Inc 8-anilinoimidazopyridine und ihre verwendung als antikrebsmittel und/oder entzündungshemmende mittel
MX2010006800A (es) 2007-12-19 2010-10-05 Genentech Inc 5-anilinoimidazopiridinas y metodos de uso de las mismas.
PT2288610T (pt) 2008-03-11 2016-10-17 Incyte Holdings Corp Derivados de azetidina e de ciclobutano como inibidores de jak
RS52712B (en) * 2008-04-11 2013-08-30 Janssen Pharmaceutica N.V. THIAZOLOPYRIDIN-2-ILOXY-PHENYL I THIAZOLOPYRZIN-2-ILOXY-PHENYL KAO MODULATOR FOR LEUKOTRIEN A4 HYDROLAZE
WO2009132202A2 (en) 2008-04-24 2009-10-29 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
WO2009151910A2 (en) * 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
US20110230467A1 (en) * 2008-11-21 2011-09-22 Astellas Pharma Inc. 4,6-diaminonicotinamide compound
WO2010085597A1 (en) 2009-01-23 2010-07-29 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
DK2432472T3 (da) 2009-05-22 2019-11-18 Incyte Holdings Corp 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octan- eller heptan-nitril som jak-inhibitorer
EP2432555B1 (en) 2009-05-22 2014-04-30 Incyte Corporation N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
US9249145B2 (en) 2009-09-01 2016-02-02 Incyte Holdings Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
CA2777114C (en) 2009-10-09 2018-10-23 Incyte Corporation Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
MX364636B (es) 2010-03-10 2019-05-03 Incyte Corp Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1).
EP3087972A1 (en) 2010-05-21 2016-11-02 Incyte Holdings Corporation Topical formulation for a jak inhibitor
JP5917544B2 (ja) 2010-11-19 2016-05-18 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン
AU2011329734B2 (en) 2010-11-19 2015-05-28 Incyte Holdings Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
BR112013020798B1 (pt) 2011-02-18 2022-03-15 Incyte Corporation Uso e composição contendo uma combinação de um inibidor mtor e de um inibidor de jak para tratamento de neoplasisas mieloproliferativas
WO2012125886A1 (en) * 2011-03-17 2012-09-20 Bristol-Myers Squibb Company Pyrrolopyridazine jak3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases
TW201249846A (en) 2011-03-17 2012-12-16 Bristol Myers Squibb Co Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases
WO2012125887A1 (en) * 2011-03-17 2012-09-20 Bristol-Myers Squibb Company Pyrrolopyridazine jak3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases
CN103547580B (zh) 2011-03-22 2016-12-07 阿迪维纳斯疗法有限公司 取代的稠合三环化合物、其组合物及医药用途
KR20140040819A (ko) 2011-06-20 2014-04-03 인사이트 코포레이션 Ｊａｋ 저해제로서의 아제티디닐 페닐, 피리딜 또는 피라지닐 카르복스아미드 유도체
CA2844507A1 (en) 2011-08-10 2013-02-14 Novartis Pharma Ag Jak pi3k/mtor combination therapy
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
ES2567552T3 (es) * 2012-01-30 2016-04-25 Cephalon, Inc. Imidazo [4,5-b] derivados de piridina como los moduladores ALK y JAK para el tratamiento de trastornos proliferativos
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
ES2666353T3 (es) 2012-09-06 2018-05-04 Bristol-Myers Squibb Company Inhibidores de JAK3 de imidazopiridazina y su uso para el tratamiento de enfermedades inflamatorias y autoinmunitarias
US9593115B2 (en) 2012-09-21 2017-03-14 Advinus Therapeutics Ltd. Substituted fused tricyclic compounds, compositions, and medicinal applications thereof
EP3949953A1 (en) 2012-11-15 2022-02-09 Incyte Holdings Corporation Sustained-release dosage forms of ruxolitinib
EP3489239B1 (en) 2013-03-06 2021-09-15 Incyte Holdings Corporation Processes and intermediates for making a jak inhibitor
PT3030227T (pt) 2013-08-07 2020-06-25 Incyte Corp Formas de dosagem de libertação prolongada para um inibidor de jak1
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
WO2017009751A1 (en) 2015-07-15 2017-01-19 Pfizer Inc. Pyrimidine derivatives
CN107513067A (zh) 2016-06-16 2017-12-26 北京赛林泰医药技术有限公司 含有取代环戊基的吡咯并嘧啶化合物
JP2020502070A (ja) 2016-11-30 2020-01-23 ケース ウエスタン リザーブ ユニバーシティ １５−ｐｇｄｈ阻害剤とコルチコステロイドおよび／またはｔｎｆ阻害剤との組み合わせならびにその使用
US11718589B2 (en) 2017-02-06 2023-08-08 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
CN111479814A (zh) * 2017-12-13 2020-07-31 葛兰素史密斯克莱知识产权发展有限公司 作为h-pgds抑制剂的稠合的吡啶
AR114810A1 (es) 2018-01-30 2020-10-21 Incyte Corp Procesos e intermedios para elaborar un inhibidor de jak
MX2022012285A (es) 2018-03-30 2023-08-15 Incyte Corp Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak).
US20220267348A1 (en) * 2019-07-23 2022-08-25 Bristol-Myers Squibb Company Thienopyridinyl and thiazolopyridinyl compounds useful as irak4 inhibitors
KR20220107213A (ko) 2019-11-22 2022-08-02 인사이트 코포레이션 Alk2 억제제 및 jak2 억제제를 포함하는 병용 요법
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3996233A (en) * 1975-02-10 1976-12-07 E. R. Squibb & Sons, Inc. Amino derivatives of imidazo[4,5-b]pyridines
CA1077484A (en) * 1975-03-05 1980-05-13 E.R. Squibb And Sons Amino derivatives of thiazolo (5,4-b) pyridine-6-carboxylic acids and esters
US3953461A (en) * 1975-03-05 1976-04-27 E. R. Squibb & Sons, Inc. Amino derivatives of thiazolo[5,4-b]pyridine-6-carboxylic acids and esters
US6992188B1 (en) * 1995-12-08 2006-01-31 Pfizer, Inc. Substituted heterocyclic derivatives
US6107300A (en) * 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
SE0101675D0 (sv) 2001-05-11 2001-05-11 Astrazeneca Ab Novel composition
SE0301372D0 (sv) * 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
AU2004236144A1 (en) 2004-11-18
CA2524624A1 (en) 2004-11-18
DE602004011330T2 (de) 2009-01-15
ES2298754T3 (es) 2008-05-16
DK1625126T3 (da) 2008-03-31
AU2004236144B2 (en) 2008-02-14
PL1625126T3 (pl) 2008-07-31
EP1887007A3 (en) 2008-03-26
ATE384061T1 (de) 2008-02-15
JP2006525997A (ja) 2006-11-16
DE602004011330D1 (de) 2008-03-06
MXPA05012025A (es) 2006-02-03
CN1784402A (zh) 2006-06-07
US20060287355A1 (en) 2006-12-21
BRPI0410081A (pt) 2006-05-16
WO2004099204A1 (en) 2004-11-18
CY1107301T1 (el) 2012-11-21
EP1625126B1 (en) 2008-01-16
PT1625126E (pt) 2008-03-10
EP1625126A1 (en) 2006-02-15
EP1887007A2 (en) 2008-02-13

Similar Documents

Publication Publication Date Title
SE0301373D0 (sv) Novel compounds
SE0301372D0 (sv) Novel compounds
SE0101675D0 (sv) Novel composition
CY1109998T1 (el) Ενδυναμωτες υποδοχεων γλουταμινικου
EA200700188A1 (ru) Производные замещенного 2-алкилхиназолинона как ингибиторы parp
EA200970156A1 (ru) Пиридизиноновые производные
EA200801608A1 (ru) Производные бензимидазолонкарбоновой кислоты
SE0303180D0 (sv) Novel compounds
SE0302232D0 (sv) Novel Compounds
ATE433447T1 (de) Pyrimiidinverbindungen
EA200700185A1 (ru) Производные хиназолиндиона в качестве ингибиторов parp
NO20056192L (no) Kapaseinhibitorer og anvendelse derav
WO2006050161A3 (en) Therapeutic furopyrimidines and thienopyrimidines
WO2006039718A3 (en) Aryl nitrogen-containing bicyclic compounds and their use as kinase inhibitors
CY1109006T1 (el) Παραγωγα πουρινης ως αναστολεις κινασης
HK1110588A1 (en) Novel phenylaminopyrimidine derivatives as inhibitors of bcr-abl kinase
HRP20070043A2 (en) Antiviral compounds
EA200700166A1 (ru) 4-замещённые производные хинолина, способ получения и промежуточные вещества для их приготовления и содержащие их фармацевтические композиции
EA200601007A1 (ru) 7-фенилалкилзамещённые 2-хинолиноны и 2-хиноксалиноны в качестве ингибиторов поли(адф-рибоза)полимеразы
WO2004106293A3 (en) Oxazolyl - and thiazolyl - purine based tricyclic compounds.
NO20064344L (no) Caspaseinhibitorer og anvendelser derav
NO20054361D0 (no) Benzensylfonamidderivater, fremgangsmate for fremstilling og anvendelse derav for behandlig av smerte
EA200600605A1 (ru) Перегруппированные пентанолы, способ их получения и их применение в качестве противовоспалительных средств
DK1448562T3 (da) Substituerede tetracycliske pyrroloquinolonderivater egnede som phosphodiesteraseinhibitorer
BR0318521A (pt) arilindenopiridinas e arilindenopirimidinas e métodos terapêuticos e profiláticos relacionados